2025 Conference Coverage: Optimizing the Holistic Health of Patients with Narcolepsy and IH: Meetings to Make Heart and Health Connections – Day Three

This program is supported by an independent medical education grant from Jazz Pharmaceuticals.

Meet the Faculty:

Richard K. Bogan MD, FCCP, FAASM 
Associate Clinical Professor 
University of South Carolina School of Medicine 
Principal, Bogan Sleep Consultants, LLC 
Columbia, SC 

June 11th, 2025:

Abstracts:

Insights From Physician Notes Into Management Of Patients With Narcolepsy Type 2 And Idiopathic Hypersomnia (IH)

The Clinical and Humanistic Burden of Narcolepsy: Matched Analysis of US National Health and Wellness Survey Data

Describing the Healthcare Providers of Patients With Narcolepsy or Idiopathic Hypersomnia in US Clinical Practice

Disclosures:

Dr. Bogan reports the following financial relationships:  

Consultant: Alkermes; Apnimed, Inc.; Avadel; Daiichi Sankyo, Inc.; Eisai Inc.; Harmony Biosciences; and Takeda Pharmaceutical Company Limited 

Research Support: Apnimed, Inc.; AstraZeneca; Avadel; Axsome Therapeutics, Inc.; Balance; Bayer; Bresotec Medical; Centessa Pharmaceuticals; Eisai Inc.; Fisher & Paykel Healthcare Limited; Fresca Medical, Inc.; Idorsia Pharmaceuticals; Insilico Medicine; Jazz Pharmaceuticals, Inc.; LivaNova; Merck & Co., Inc.; Mineralys Therapeutics, Inc.; NLS Pharmaceutics; Noctrix; Oura; Philips; Rho, Inc.; Roche; Sanofi; Sommetrics, Inc.; Suven Life Sciences; Takeda Pharmaceutical Company Limited; Zevra Therapeutics; and ZiO Health Ltd 

Speakers Bureau for Axsome Therapeutics, Inc.; Eisai Inc.; Harmony Biosciences; Idorsia Pharmaceuticals; and Jazz Pharmaceuticals, Inc. 

Shareholder: Healthy Humming, LLC and Watermark Medical 

Board of Directors: Watermark Medical